Ibogaine is a “plant-based psychoactive substance derived from the iboga shrub, a plant native to Central Africa,” according to UTHealth Houston. In …
Psyence BioMed Secures GMP Ibogaine Supply, First 50kg Arrives | PBM Stock News
With PsyLabs, Psyence BioMed secures GMP ibogaine from sustainable iboga bark, processing 50 kg into ibogaine HCL and Total Alkaloid Extracts for …
Psychedelic Medicine Leader Expands Clinical Trials, Reports $11.4M Cash Position
Psyence BioMed (NASDAQ: PBM) provided a comprehensive corporate update highlighting significant progress across multiple fronts. The company reported a strong cash position of $11.4 million with no outstanding debt and successfully regained Nasdaq compliance following a 1-for-7.97 reverse stock split.
Key developments include protocol amendments to expand patient eligibility in clinical trials, activation of three ...